M
Muriel D. David
Researcher at Institut Gustave Roussy
Publications - 34
Citations - 2384
Muriel D. David is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Cellular differentiation & IDH2. The author has an hindex of 21, co-authored 33 publications receiving 1962 citations. Previous affiliations of Muriel D. David include Université Paris-Saclay & University of British Columbia.
Papers
More filters
Journal ArticleDOI
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine E. Yen,Jeremy Travins,Fang Wang,Muriel D. David,Muriel D. David,Erin Artin,Kimberly Straley,Anil K. Padyana,Stefan Gross,Byron DeLaBarre,Erica Tobin,Yue Chen,Raj Nagaraja,Sung Choe,Lei Jin,Zenon D. Konteatis,Giovanni Cianchetta,Jeffrey O. Saunders,Francesco G. Salituro,Cyril Quivoron,Cyril Quivoron,Paule Opolon,Olivia Bawa,Véronique Saada,Véronique Saada,Angelo Paci,Sophie Broutin,Olivier Bernard,Olivier Bernard,Stéphane de Botton,Stéphane de Botton,Benoit S. Marteyn,Benoit S. Marteyn,Monika Pilichowska,Yingxia Xu,Cheng Fang,Fan Jiang,Wentao Wei,Shengfang Jin,Lee Silverman,Wei Liu,Hua Yang,Lenny Dang,Marion Dorsch,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Scott A. Biller,Shin-San Michael Su +47 more
TL;DR: It is shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development.
Journal ArticleDOI
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Michael Amatangelo,Lynn Quek,Alan Shih,Eytan M. Stein,Mikhail Roshal,Muriel D. David,Benoit S. Marteyn,Noushin Farnoud,Stéphane de Botton,Olivier A. Bernard,Bin Wu,Katharine E. Yen,Martin S. Tallman,Elli Papaemmanuil,Virginie Penard-Lacronique,Anjan Thakurta,Paresh Vyas,Ross L. Levine +17 more
TL;DR: In this article, the authors measured 2-HG, mIDH2 allele burden, and cooccurring somatic mutations in sequential patient samples from the clinical trial and correlated these with clinical response.
Journal ArticleDOI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller,Lemieux Rene M,Erin Artin,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Giovanni Cianchetta,Zhenwei Cai,Ding Zhou,Cui Dawei,Ping Chen,Kimberly Straley,Erica Tobin,Fang Wang,Muriel D. David,Virginie Penard-Lacronique,Cyril Quivoron,Véronique Saada,Stéphane de Botton,Stefan Gross,Lenny Dang,Hua Yang,Luke Utley,Yue Chen,Hyeryun Kim,Shengfang Jin,Zhiwei Gu,Gui Yao,Zhiyong Luo,Xiaobing Lv,Cheng Fang,Liping Yan,Andrew J. Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Katharine E. Yen +36 more
TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.
Journal ArticleDOI
Distinct structural features of caprin-1 mediate its interaction with G3BP-1 and its induction of phosphorylation of eukaryotic translation initiation factor 2alpha, entry to cytoplasmic stress granules, and selective interaction with a subset of mRNAs.
Samuel Solomon,Yaoxian Xu,Bin Wang,Muriel D. David,Peter Schubert,Derek Kennedy,John W. Schrader +6 more
TL;DR: It is demonstrated that Caprin-1 colocalizes with RasGAP SH3 domain binding protein-1 (G3BP-1) in cytoplasmic RNA granules associated with microtubules and concentrated in the leading and trailing edge of migrating cells.
Journal ArticleDOI
Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
A. Francesca Setiadi,Kyla D. Omilusik,Muriel D. David,Robyn P. Seipp,Jennifer Hartikainen,Rayshad Gopaul,Kyung Bok Choi,Wilfred A. Jefferies +7 more
TL;DR: It is observed that TSA treatment suppresses tumor growth and increases tap-1 promoter activity in TAP-deficient tumor cells in vivo, and novel insights into the molecular mechanisms controlling tumor immune escape may help revise immunotherapeutic modalities for eradicating cancers.